This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.
• Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week).
Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose.
Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication.
Age between 18 and 70 years.
• Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis).
History of prior upper gastrointestinal resection (stomach, intestine, or esophagus).
Any other condition deemed inappropriate by the treating physician.
Body mass index (BMI) > 40 kg/m².
Map coordinates are unavailable for these locations. Locations are shown below instead.
Taiwan